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Background: Only a subset of patients who enter stage 3 chronic kidney disease (CKD) progress to stage 4.
Identifying which patients entering stage 3 are most likely to progress could improve outcomes, by allowing more
appropriate referrals for specialist care, and spare those unlikely to progress the adverse effects and costliness of an
unnecessarily aggressive approach. We hypothesized that compared to non-progressors, patients who enter stage
3 CKD and ultimately progress have experienced greater loss of renal function, manifested by impairment of
metabolic function (anemia, worsening acidosis and mineral abnormalities), than is reflected in the eGFR at entry
to stage 3. The purpose of this case-controlled study was to design a prediction model for CKD progression using
laboratory values reflecting metabolic status.
Methods: Using data extracted from the electronic health record (EHR), two cohorts of patients in stage 3 were
identified: progressors (eGFR declined >3 ml/min/1.73m2/year; n = 117) and non-progressors (eGFR declined <1 ml/
min/1.73m2; n = 364). Initial laboratory values recorded a year before to a year after the time of entry to stage 3,
reflecting metabolic complications (hemoglobin, bicarbonate, calcium, phosphorous, and albumin) were obtained.
Average values in progressors and non-progressors were compared. Classification algorithms (Naïve Bayes and
Logistic Regression) were used to develop prediction models of progression based on the initial lab data.
Results: At the entry to stage 3 CKD, hemoglobin, bicarbonate, calcium, and albumin values were significantly
lower and phosphate values significantly higher in progressors compared to non-progressors even though initial
eGFR values were similar. The differences were sufficiently large that a prediction model of progression could
be developed based on these values. Post-test probability of progression in patients classified as progressors or
non-progressors were 81% (73% − 86%) and 17% (13% − 23%), respectively.
Conclusions: Our studies demonstrate that patients who enter stage 3 and ultimately progress to stage 4 manifest
a greater degree of metabolic complications than those who remain stable at the onset of stage 3 when eGFR
values are equivalent. Lab values (hemoglobin, bicarbonate, phosphorous, calcium and albumin) are sufficiently
different between the two cohorts that a reasonably accurate predictive model can be developed.Background
During the last decade the prevalence of chronic kidney
disease (CKD) has increased considerably and is estimated
to range from about 10-15% of the elderly population
[1-5]. Only a portion of patients with early stage 3 CKD
progress to stage 4 where the risk of cardiovascular dis-
ease, end stage renal disease (ESRD), or death becomes* Correspondence: hc15@cumc.columbia.edu
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tients who enter stage 3 and are most likely to progress to
stage 4 CKD could both improve outcomes, by allowing
more appropriate referrals for specialist care [13-16], as
well as spare those unlikely to progress the adverse effects
and costliness of an unnecessarily aggressive approach
[17,18]. This issue is particularly important in the geriatric
population in whom it is unclear whether a reduced esti-
mated glomerular filtration rate (eGFR) in the stage 3
range is associated with the poor outcomes of renaltd. This is an Open Access article distributed under the terms of the Creative
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slower progression of kidney disease [19,20].
While there are several useful prediction models based
on various features such as the presence or absence of
proteinuria, the predictive value of the majority is largely
dependent on the eGFR (or creatinine) [21,22]. Predict-
ing the risk of progressing to stage 4 in patients newly
diagnosed in stage 3, however, could only be accom-
plished with a model that did not use eGFR as a predict-
ive feature given that the eGFR in all patients entering
stage 3 is the same, by definition, regardless of whether
the patient goes on to progress to stage 4.
We explored the hypothesis that compared to non-
progressors, patients who enter stage 3 CKD and ultim-
ately progress have experienced greater loss of renal
function, manifested by impairment of metabolic func-
tion (anemia, worsening acidosis and mineral abnormal-
ities), than is reflected in the eGFR at entry to stage 3.
Presumably, progression would be less likely if the de-
cline in GFR were due to a reduction in renal plasma
flow, associated with normal aging [23-26], with minimal
parenchymal loss and the absence of a distinct renal dis-
ease. The association of proteinuria and progression
supports the view that when patients reach stage 3 they
have greater or lesser degrees of renal injury, which in-
fluence the likelihood of progression [10,27-29]. Protein-
uria, however, is not a direct measure of functioning
parenchyma but rather reflects renal injury. Not all pa-
tients with proteinuria are destined to progress, possibly
reflecting a subgroup that has not suffered parenchymal
loss. A more direct assessment of reduced functional
parenchyma might be the presence of metabolic compli-
cations, which include reduced hemoglobin [30] and
dysregulation of acid-base balance [31] and mineral me-
tabolism [32], well-known to be present in patients with
advanced chronic kidney disease. Recent investigations
have demonstrated that metabolic complications can be
observed as early as stage 3 and that the prevalence in-
creases as GFR (or eGFR) declines [33-42]. Given the
cross-sectional nature of these studies, however, it could
not be determined if patients with early onset metabolic
complications were more likely to proceed to stage 4.
The purpose of our longitudinal study was to explore
the association of metabolic complications and progres-
sion of CKD. We compared average values of hemoglobin,
bicarbonate, calcium, phosphorous and albumin in pa-
tients demonstrated to progress to those who did not. We
also compared minimum (or maximum) values of each of
these features hypothesizing that patients less able to
achieve metabolic balance might experience wider swings
in concentrations of metabolic lab values. To test whether
any differences in metabolic lab data observed between
progressors and non-progressors were of sufficient magni-
tude to serve as useful attributes in a prediction model, weused classification algorithms to create a model based ex-
clusively on these lab data.
Methods
Identification of patients with progressive or non-
progressive stage 3 CKD
The data source for this study was the clinical data
warehouse of the Columbia University Medical Center
(CUMC) of the New York Presbyterian Hospital. Patients
whose records were used in this study were regularly cared
for in the Associates of Internal Medicine (AIM) primary
care clinic for adults (age 21 and older) on the CUMC
campus. The study was performed with the approval of
the CUMC Institutional Review Board in compliance with
the Helsinki Declaration. The Institutional Review Board
did not require written informed consent for participation
in the study and granted a waiver given the nature of the
study (to analyze data from the data warehouse, which is
not considered a potential risk to a patient).
Our goal was to identify a cohort of patients who both
met the current National Kidney Foundation definition
of stage 3 CKD (KDOQI, [13]) and had sufficient data in
their record to determine whether or not their eGFR
had either progressively declined or remained stable over
several years. From an initial screen of over 10,000
patients cared for in the AIM clinic, from 2006-2012, a
cohort of approximately 700 were identified with stage 3
CKD (patient selection is summarized in Figure 1).
Estimated GFR for each patient was calculated using the
four-variable Modification of Diet in Renal Disease
(MDRD) formula [43] based on the patient’s creatinine
values, gender, race (African American or not), and
age, data extracted from the clinical data warehouse.
Standardization of creatinine measurements is cali-
brated to IDMS. Only patients with 5 visits or more
were included to ensure sufficient data to determine if
they were progressors of non-progressors. Patients
were excluded if they were consistently in stage 4, had
received a kidney transplant, had ICD-9 code docu-
mentation of diseases known to cause rapid loss of renal
function (primary glomerulonephritis, HIV-AIDS, or sys-
temic lupus erythematosus) or of nephrotic syndrome.
Patients were followed an average of 6.0 (SD 2.9) years
and the majority (87%) had four consecutive years of data
available.
Progressors (P) and non-progressors (NP) were identi-
fied on the basis of the slope of the changes of eGFR
over time [44]. For each patient with at least 4 or more
measurements of creatinine over a period of four years,
a linear regression of eGFR versus time was performed
yielding a slope and standard error. Progressors were de-
fined as those patients whose eGFR declined at a rate
greater than 3 ml/min/1.73m2 per year (slope of < −3.0 ml/
min/1.73m2/year), significantly different from 0 (p <0.05)
Figure 1 Patient selection algorithm.
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whose eGFR did not decline meaningfully over time (slopes
between −1.0 and +1.0 ml/min/1.73m2/year). There were
117 and 364 P and NP patients, respectively.
Data acquisition
Lab data and diagnosis data for co-morbid conditions were
extracted for analysis and classification. Labs extracted in-
cluded hemoglobin, bicarbonate, phosphorous, calcium, al-
bumin and dipstick protein in a urinalysis. For analysis and
model-building the dipstick results were converted to num-
bers: none = 0; trace = 0.5; 1+, 2+, 3+, 4+ = 1, 2, 3 and 4,respectively. Diagnosis data was recorded in the EHR using
International Classification of Diseases, version 9 (ICD-9)
codes. Two data sets were generated: initial and follow-up.
Initial data was collected for each patient from one year
before the start date of sustained stage 3 CKD through one
year after. Follow-up data on these same patients was col-
lected when they had been in stage 3 (or higher) for more
than 3-5 years (average of approximately 5 years).
Predictive modeling
Using the Weka workbench [47], we developed a pre-
dictive model using logistic regression and Naïve Bayes
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been in stage 3 for several years. The model was then
used on the testing set (the initial data) to see how well
the model could predict which patients were likely to
progress when they first entered stage 3. Models were
validated and accuracy assessed by calculating sensitivity,
specificity, and the area under the curve (AUC) of the
receiver-operating characteristic (ROC). Patients were
also randomized into separate training and testing sets;
models built using half the patients were tested on the
lab values of the other half of the patients.
Statistics
For continuous values, the Student t-test was used to
determine significance. For categorical values, the Chi-
squared test was used. Regression analysis was conducted
using standard methodology implemented through a Java
framework. Likelihood ratios and positive and negative
predictive values were calculated from sensitivity and spe-
cificity. Post-test probabilities were calculated from likeli-
hood ratios using logarithmic transformation [48].
Results
General characteristics of progressors and
non-progressors
P were significantly younger than NP: average ages were
71.3(SD 11) and 75.9 (SD 11), respectively (Table 1). The
percentage of progressors who were African American
was significantly higher (7.6%) than in non-progressors
(2.5%) (p <0.01). There was no significant gender differ-
ence between the two groups: 61.3% of progressors were
female compared to 65.2% of the non-progressors (p =
0.59). Though a sizable proportion of both P and NP
had diabetes ICD-9 codes in their EHR (75.6%, 62.8%,
respectively); the proportion was significantly higher in P
(p = 0.015). CKD progression was not significantly associ-
ated with having received an ICD-9 code for hypertension.
Variability of lab values
There was significant intra-patient variation of eGFR
and other laboratory values. Fluctuations of eGFR in pa-
tients who did not progress over many years showedTable 1 Demographics and co-morbid conditions of NP
and P patients
Patient Attribute NP P
characteristics
Demographics Female 65.2% 61.3%
African American** 2.5% 7.6%
Age** 75.9 (SD 11) 71.3 (SD 11.7)
Co-Morbid conditions Diabetes* 62.8% 75.6%
Hypertension 99.2% 100%
Significance levels: **p < 0.01; *p <0.05.swings as wide as 40 ml/min/1.73m2. Given the intra-
patient variability, we calculated and compared average
initial values over a 2 year time period, a year before and
a year after the start date of stage 3 CKD (see below) for
each patient to be used in the analysis and modeling.
We also extracted the minimum and maximum values.
The coefficients of variation and the difference between
the average maximum and minimum values of several
laboratory tests are presented in Table 2.
Identification of CKD stage 3 start date
While most patients who entered stage 3 CKD remained
in stage 3 (or higher) for the duration of their electronic
record of data, there were some whose eGFR intermit-
tently rose above 60 ml/min/1.73m2, an observation
expected following the demonstration of the large coeffi-
cient of variation of eGFR values (Table 2). We chose
the date on which patients developed sustained stage 3
CKD to be that when eGFR remained consistently below
60 ml/min/1.73m2 for at least one year.
Lab values reflecting metabolic complications of renal
disease
Progressors and non-progressors had similar initial aver-
age eGFR values at the time of entry to stage 3 (Table 3).
Progressors, however, were found to have significantly
lower minimum values of eGFR at the time they entered
stage 3. Average values of both P and NP were below
the usual stage 3 cut-off of 59 ml/min/1.73m2 due to
periodic dips of eGFR to values below 40 ml/min/1.73m2
(see MIN, Table 3) and reflecting the requirement that pa-
tients’ eGFR was <60 ml/min/1.73m2 for at least one year
rather than the KDOQI defined 90 days. Average and
minimum (or maximum) initial values for plasma bicar-
bonate, hemoglobin, calcium, phosphorous, and albumin
were significantly different between P and NP.
Follow-up data, used as the training set for classifica-
tion model building, are also presented in Table 3. As
expected, average and minimum eGFR values collected
from patients who had been in stage 3 or 4 for several
years were significantly lower in P versus NP. The differ-
ences in hemoglobin, bicarbonate, calcium and phos-
phorous between P and NP, observed in the initial data,
was magnified in the follow-up data. Parathyroid hor-
mone levels were significantly higher in P than NP, 179Table 2 Intra-patient variation of lab values
Attribute Coefficient of variation Maximum-minimum spread
eGFR 0.14 (SD 0.11) 12 (SD 9), ml/min/1.73m2
Phosphorous 0.13 (SD 0.13) 1.8 (SD 1.6), mg/dl
Bicarbonate 0.09 (SD 0.05) 6.8 (SD 4.5), meq/l
Potassium 0.09 (SD (0.01) 1.3 (SD 1.3), meq/l
Hemoglobin 0.06 (SD 0.06) 2.2 (SD 2.2), g/dl
Table 3 Lab tests values





eGFR [100%] MIN P 34 20
NP 39 34
Δ −5 *** −14 ***
MAX P 57 44
NP 58 49
Δ −1 NS −5 ***
AVG P 47 34
NP 48 44
Δ −1 NS −10 ***
HEMOGLOBIN [92%] MIN P 10.9 9.6
NP 11.5 11.0
Δ −0.7 ** −1.4 ***
AVG P 12.0 11.3
NP 12.6 12.3
Δ −0.5 *** −1.0 ***
BICARBONATE [100%] MIN P 20.7 16.9
NP 21.8 19.6
Δ −1.1 ** −2.7 ***
AVG P 24.1 23.0
NP 25.1 24.5
Δ −0.9 *** −1.4 ***
CALCIUM [100%] MIN P 8.5 7.9
NP 8.6 8.2
Δ −0.2 * −0.4 ***
AVG P 9.1 9.0
NP 9.2 9.2
Δ −0.1 *** −0.2 ***
PHOSPHOROUS [53%] MAX P 4.1 5.2
NP 3.7 4.3
Δ 0.4 ** 0.9 ***
AVG P 3.6 3.9
NP 3.3 3.4
Δ 0.3 *** 0.4 ***
ALBUMIN [95%] MIN P 3.7 3.1
NP 3.9 3.5
Δ −0.2 ** −0.5 ***
AVG P 4.0 3.9
NP 4.1 4.1
Δ −0.2 *** −0.2 ***
Table 3 Lab tests values (Continued)
DIPSTICK PROTEIN [57%] MAX P 1.4 2.2
NP 0.5 0.9
Δ 0.9 ** 1.4 ***
AVG P 1.1 1.4
NP 0.4 0.5
Δ 0.7 *** 1.0 ***
Displayed are average, minimum or maximum values of P and NP, and the
difference between them (Δ). Initial and follow-up data (see Methods) are
presented separately. Negative numbers indicate that the value is lower in P;
positive numbers, higher. Statistical significance of differences: ***p <0.001;
**p <0.01; *p <0.05; NS, not significant. % of values under test name indicate
proportion of patients having had the test.
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25 Vitamin D levels were significantly lower in P than
NP, 26 (SD 11) and 38 (SD 15) ng/ml (p <0.005), re-
spectively. However, too few patients had either PTH or
Vitamin 1,25 D values measured during the initial
period, at the time of entry to stage 3, to provide for a
meaningful comparison between P and NP.Proteinuria
Fewer than 60% of patients had results of a urinary dip-
stick for protein in their electronic health record. Of
these patients, the initial average and maximum values
of qualitative urine protein were significantly different
between P and NP (Table 3). Approximately 50% of pro-
gressors had significant proteinuria (2+ - 4+) while 70%
of non-progressors had little or no proteinuria (0-trace).Predictive modeling using lab data
To determine if the differences in initial lab data (Table 3)
between the progressors and non-progressors at the time
of entry to stage 3 was predictive of progression, we used
classification algorithms, generated from the training set,
on the initial data (testing set). The eGFR data was not in-
cluded as an attribute for model building given that the
initial values were similar in P and NP. Sensitivity, specifi-
city and positive and negative likelihood ratios generated
by the classification are presented in Table 4. Naïve Bayes
generated the higher sensitivity, 72% (CI 63% −80%) and
logistic regression generated the higher specificity, 89%
(CI 85% −92%). The ROC AUC was similar for both algo-
rithms (0.73, 0.75, respectively). Post-test probabilities of ei-
ther being a progressor or non-progressor, based on
classification, were calculated assuming a prevalence of
progression of approximately 40% [11]. Using the higher
specificity generated by logistic regression and the higher
sensitivity generated by Naïve Bayes yielded post-test prob-
abilities for classification as a progressor or non-progressor
were 81% (73% − 86%) and 17% (13% − 23%), respectively.
Table 4 Accuracy of classification algorithms based on
initial metabolic data laboratory values
Naïve Bayes Logistic regression
Statistic Value 95% confidence Value 95% confidence
Sensitivity 72% 63% −80% 43% 34% −52%
Specificity 65% 60% −70% 89% 85% −92%
LR+ 2.06 1.72 − 2.46 3.79 2.66 − 5.42
LR- 0.43 0.32 − 0.58 0.65 0.55 − 0.76
PPV 58% 53% −62% 72% 64% −78%
NPV 22% 18% −28% 30% 27% −34%
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CKD-related metabolic complications in patients who
progress
The purpose of this study was to design a prediction
model for CKD progression using laboratory values
other than eGFR based on the hypothesis that patients
who enter stage 3 and ultimately progress have sustained
a greater loss of renal function, manifested by impair-
ment of metabolic function, than is reflected in the
eGFR at stage 3 entry, compared to non-progressors. Fu-
ture progressors had already developed metabolic com-
plications by the time they entered stage 3 CKD, despite
no differences in initial eGFR between progressors and
non-progressors. Hemoglobin, bicarbonate, calcium, and
albumin levels were significantly lower, and phosphate
significantly higher in the progressors (Table 3). The dif-
ferences between the two groups were magnified when
maximum or minimum values were compared. These
results confirm and extend prior work demonstrating
that metabolic complications can be observed in patients
as early as stage 3 and that the prevalence increases as
GFR (or eGFR) declines [33-41]. Our study, which fol-
lows patients longitudinally, directly demonstrates the
association of metabolic complications and progression.
In our study, given that these laboratory measurements
are measured on most patients in a screening metabolic
panel far more than urine protein measurements, the
ability to use them in a prediction model for CKD pro-
gression could be very useful.
It is unclear why future CKD progression is associated
with early metabolic complications. One explanation is
that future progressors have an ongoing disease process,
which results in greater parenchymal injury and meta-
bolic complications, which is absent in non-progressors,
and not yet reflected in the eGFR. One example of an
ongoing disease process inflicting damage would be
diabetes. In our cohort, there was a significantly higher
prevalence of diabetes in progressors than in non-
progressors (Table 1). This difference, however, was
small, possibly due to sample size not being powered to
look for this difference. Furthermore, given the use ofICD-9 codes, we could not distinguish between a patient
with diabetes and concomitant and unrelated CKD, and
a patient felt to have CKD from diabetes. On average,
progressors had a higher level of proteinuria (Table 3),
possibly reflecting a higher prevalence of diabetic kidney
disease in this group. Lastly, we did not assess either the
degree of glycemic control [49] or the use of RAS inhibi-
tors to control hypertension. If the use of RAS inhibitors
was higher in the patients with diabetes who did not
progress, this difference could explain why some pa-
tients with diabetes progressed and others did not. Given
our exclusion criteria, it is also unlikely that the progres-
sors suffered from a primary disease, such as glomerulo-
nephritis, known to cause progressive renal failure. It thus
remains unclear what underlying process might be respon-
sible for early metabolic abnormalities being associated with
future CKD progression but seems likely that it represents
an early loss of non-filtration function that can be used to
categorize patients into higher and lower risk groups.
Our observation that non-progressors do not manifest
metabolic complications suggests that these patients
might have less parenchymal loss than the progressors.
The basis of the reduced eGFR may be due to dimin-
ished blood flow with reduced renal reserve preventing
compensatory hyperfiltration [50-52]. Not distinguishing
between these two groups and using the term “chronic
kidney disease” to characterize patients in whom there is
only a decline in the glomerular filtration without other
manifestations of disease is not clinically useful [18,53,54].
A better term for such patients might be “chronic renal in-
sufficiency” (CRI) a previously commonly used term that
that was retired with the introduction of the KDOQI sta-
ging guidelines [18,54]. The distinction between CKD and
CRI is particularly important in the elderly given the
declines in eGFR related to aging and reduced renal re-
serve [12,23,52]. Lower eGFRs may inappropriately label
subjects with CKD when in fact they have only age related
declines in renal function and are unlikely to have pro-
gressive renal disease. Compensatory hyperfiltration at the
early stages of reduced renal mass only adds to the diffi-
culty associated with identifying patients with true renal
disease. In addition to possibly leading to over-referral and
treatment of patients without true kidney disease, this
lumping of all patients with reduced eGFR into the same
stages also leads to an inability to target those who are
most at risk to progress at an early stage when perhaps
intervention has the most hope of improving outcomes.
Current staging of CKD
The apparent uncoupling of filtration (eGFR) and meta-
bolic renal function suggests that the current staging
paradigm, based primarily on eGFR for stages 3 and
higher, is not useful in estimating the degree of renal
parenchymal injury and likelihood of progression. More
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stage 3A (<60 and >45 ml/min/1.73m2) and stage 3B
(<45 and >30 ml/min/1.73m2) and take into consider-
ation the degree of proteinuria. [55]. While the presence
of proteinuria clearly signifies renal injury, and is pre-
dictive of progression [10,28], it does not directly reflect
loss of non-filtration renal function. Nearly half our pa-
tients who progressed and manifested complications of
CKD did not have significant proteinuria. Furthermore,
of our own cohort of patients with established CKD,
routinely seen in clinic for an average of 5 years, nearly
half did not have a urine dipstick measurement, making
it more difficult to use proteinuria as a marker of pro-
gression in real clinical practice. It has been suggested
that the staging algorithm consider the presence or ab-
sence of metabolic renal complications [38] which are
currently not included [56]. Following the KDOQI
guidelines to screen for metabolic complications upon
entry to stage 3 [13] would enable physicians to assess
the degree to which they are present.
Inter-patient variability of eGFR values
Our study showed a substantial inter-patient fluctuation
of eGFR likely the results of the inherent variability of
the creatinine measurement [57] and changes in volume
status, blood pressure, or the effect of medicines taken.
The variability poses several problems for classifying pa-
tients and predicting outcomes. First, patients diagnosed
with stage 3 CKD using the KDOQI guideline of 90 days
might subsequently be found to be in stage 2 when their
eGFRs rise above 60 ml/min/1.73m2 [56]. Prior studies
have found that over 20% of patients identified as being
in stage 3 move back into stage 2 sometime later [58].
For these reasons, we defined stage 3 as of eGFR <60 for
at least one-year. Second, recently developed tools that
provide a prediction of the time course to end stage
renal failure [22,31] if based on a single value, would
provide widely disparate estimates of the probability of
progression. However, if the algorithm were based on
average values rather then individual ones, the accuracy
of the staging would be improved and more consistent.
Third, wide eGFR fluctuations will complicate the use of
decision support tools designed to identify CKD patients
through electronic health records. Studies have shown
poor detection of CKD [59-62] suggesting the potential
utility of automated method to identify patients with
CKD through the electronic health record. If the pa-
tients are coded stage 3 only to have that reversed on
subsequent measurements of eGFR, providers will lose
confidence and ignore the notifications.
Predicting which stage 3 patients are likely to progress
The sooner it can be established that a patient is likely
to progress from stage 3 to stage 4 CKD, the earlierreferral and aggressive intervention could be imple-
mented [13-16]. Accurate prediction might also reduce
over-referral, which subjects patients to unnecessary
treatment and results in over utilization of limited
resources.
To calculate the risk of CKD progression, investigators
have focused on conditions that cause renal decline (such
as diabetes or hypertension), abnormalities that result
from renal injury (such as proteinuria) [10,17,21,39,63] or
factors known to accelerate progression (such as smoking
or obesity) [9,64,65]. Some models use end stage renal dis-
ease or death as an endpoint [30,31,66] while others use
progression itself [45,46,67,68].
The majority of currently available prediction models
are based primarily on the eGFR or creatinine; the lower
the eGFR the greater the risk of progression to end stage
[21,22]. The use of serum creatinine to predict CKD
progression is particularly challenging in elderly patients
in whom changes in muscle mass make creatinine a less
accurate marker for GFR. Models that attempt to distin-
guish individuals with age related decline in renal func-
tion from those with truly impaired renal function, and
at risk of continued progression as a result, might be
more accurate in using other measures of renal paren-
chymal function besides eGFR.
Our observation that metabolic complications occur
early in stage 3, are associated with progression, and have
predictive value suggests that models should include
markers of metabolic status laboratory data in the model.
This is especially true if metabolic complications, once de-
veloped, also accelerate progression [34,44,52,69-73]. In our
model based solely on metabolic lab data, post-test prob-
abilities for progression or non-progression were 81%
(73% − 86%) and 17% (13% − 23%), respectively, sufficiently
accurate to serve as a useful clinical tool. The ROC AUC
achieved by the classifier (~0.74) compares favorably to
those models that rely on eGFR or creatinine [22].
Halbesma et al developed a renal risk score to predict pro-
gression of CKD and demonstrated superior predictive ac-
curacy (ROC AUC was 0.84) [45] but included the initial
eGFR value as a feature and which contributed the most to
the renal risk score. Our own classification statistics should
improve as more patients have key metabolic lab values
(PTH, vitamin D) recorded in the EHR, known to be ab-
normal early in the course of renal disease [74,75].
Limitations
There are several limitations to our study. First, the total
number of patients in the P and NP group was less than
500. It is important to confirm the differences in metabolic
lab values between progressors and non-progressors and
to validate the classification models with a larger set of pa-
tients. Second, it is possible that observations of early
metabolic abnormalities in stage 3 patients from the
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female, non-white patients (Table 1) might not be ob-
served in younger, male and white patients. Future studies
will be required to determine if the same differences
are seen in a different demographic. Third, we used the
MDRD formula to calculate eGFR rather than the CKD-
EPI formula. Recent studies have demonstrated the MDRD
calculation tends to underestimate the eGFR [76,77]. How-
ever, the average MDRD eGFR values in both cohorts were
significantly below 60 ml/min/1.73m2, suggesting that pa-
tients were in stage 3 regardless of the method used to cal-
culate eGFR. Also, the two cohorts (P and NP) were
chosen on the basis of the slope of the eGFR versus time,
which is largely independent of the method of calculation.
Our conclusions regarding the association of presence of
metabolic complications and progression are thus un-
affected by the method chosen to calculate eGFR. Fourth,
although we eliminated patients with primary renal disease
from the cohorts based on their ICD-9 codes, the known
inaccuracy of ICD-9 coding [78] cannot eliminate the possi-
bility that some patients who progressed actually had a pri-
mary renal disease. Last, we used a linear regression model
to classify individuals into progressors vs. non-progressors,
an approach that does not account for the intra-individual
correlations of repeated GFR estimates over time. This ap-
proach might have resulted in misclassification of some of
the patients. This limitation will be addressed in future
studies by using a mixed effects model to classify patients.
Conclusions
Our studies demonstrate that patients who enter stage 3
and ultimately progress to stage 4 manifest a greater de-
gree of metabolic complications than those who remain
stable at the onset of stage 3 when eGFR values are
equivalent. Lab values (hemoglobin, bicarbonate, phos-
phorous, calcium and albumin) are sufficiently different
between the two cohorts that a reasonably accurate pre-
dictive model can be developed.
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